Open an account

MacroGenics

MGNX · NASDAQ

$3.49+$0.16 (+4.80%)TodayMarket closed ·
Prev close $3.33

About MGNX

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. The company is headquartered in Rockville, Maryland and currently employs 293 full-time employees. The company went IPO on 2013-10-10. The firm generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. The company is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.

Employees
293
Headquarters
Rockville, Maryland
Listed
Oct 10, 2013
Sector
Health Care
Industry
Biotechnology
Website
macrogenics.com

MGNX key statistics

Market cap
222.31M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
575.91K
Volume
325.42K
Open price
$3.35
High today
$3.60
Low today
$3.33
52 Week high
$5.08
52 Week low
$1.29

MacroGenics (MGNX) at a glance

As of Oct 20, 2026, MacroGenics (MGNX) shares are priced at $3.49, giving the company a market cap of 222.31M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.33 and $3.60. The current price is 4.8% above the day's low and 3.1% below its high.

Volume so far is 325.42K shares, below the average of 575.91K shares a day.

Over the past year MacroGenics has ranged from $1.29 to $5.08, and now sits 58% of the way up that range.

MacroGenics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.26 per share against an estimate of -$0.1283.

The average analyst price target is $9.52, 172.8% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 3 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 5 analystsAvg $9.52
Low
$6.06
Now
$3.49
High
$11.55

MGNX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 80.5% on average.

  1. Q3 FY24: reported $0.90 per share against an estimate of $0.2162
  2. Q4 FY24: reported -$0.25 per share against an estimate of -$0.4449
  3. Q1 FY25: reported -$0.65 per share against an estimate of -$0.7975
  4. Q2 FY25: reported -$0.57 per share against an estimate of -$0.6202
  5. Q3 FY25: reported $0.27 per share against an estimate of -$0.5015
  6. Q4 FY25: reported -$0.23 per share against an estimate of -$0.2964
  7. Q1 FY26: reported -$0.58 per share against an estimate of -$0.5826
  8. Q2 FY26: reported -$0.26 per share against an estimate of -$0.1283

MGNX news

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • 4 Analysts Assess Macrogenics: What You Need To Know

  • Press releaseGlobe Newswire

    Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

  • Press releaseGlobe Newswire

    MGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Similar companies

Companies in the same industry as MacroGenics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.